Charles River Laboratories (CRL) investor relations material

Strategic vision, modernization, and growth priorities

• Pathway to Purpose and Create the Future strategies focus on modernizing operations, strengthening scientific leadership, and enhancing client experience through AI, automation, and digital platforms like Apollo, targeting over $300 million in incremental savings from 2027–2030.

• Investments are prioritized in high-growth areas such as bioanalysis, NAMs, in vitro testing, and digital solutions, with ongoing organic and inorganic expansion and disciplined capital allocation.

• Four strategic priorities: reinforce scientific leadership, modernize operations, capture higher-growth opportunities, and deliver sustainable shareholder value.

• Expansion into China and other geographies is under evaluation, balancing opportunity and risk.

• Culture and talent development are emphasized, with a leadership team bringing over 400 years of industry experience.

Financial guidance and performance targets

• Long-term financial targets through 2030 include 5%–7% organic revenue CAGR (2027–2030), non-GAAP operating margin of ~24%, and low double-digit non-GAAP EPS CAGR, with 2026 guidance reaffirmed at the upper end of prior ranges.

• Margin expansion is driven by productivity improvements, automation, AI, and centralization, with $300 million+ in cost savings planned over four years.

• Capital allocation prioritizes organic growth, strategic M&A, and maintaining a strong balance sheet, with recent investments in BioA, NAMs, and manufacturing solutions.

• Segment targets: DSA aims for 5%–7% growth and >27% margins; Manufacturing Solutions targets 7%–9% growth and >40% margins; RMS targets 2%–4% growth with stable mid-20% margins.

• Pricing improvements are expected to contribute about one-third of revenue growth, with volume making up the rest.

Scientific innovation, portfolio, and business developments

• NAMs are integrated into the core business, combining in vivo, in vitro, and in silico approaches for more predictive and ethical drug development.

• Over 220 NAMs assays are in use, with test batteries for key biological areas, supporting regulatory and client decision-making.

• Virtual control groups, AI-enabled tools, and predictive analytics are reducing animal use and improving efficiency, with ongoing regulatory engagement.

• Bioanalysis expansion is a key growth lever, targeting high single-digit CAGR and $450 million revenue by 2030, shifting revenue mix toward later-stage clinical programs.

• Manufacturing Solutions leverages automation, digitalization, and next-gen sequencing (PathoQuest) to drive recurring revenue and client retention.